Company profile
Proteonomix, Inc.
OTC: PROT · Healthcare · Biotechnology
#1112 of 1,422 Healthcare companies by revenuebottom-quartile growth
EA Score
——FH —DQ —GM —SS 54
v0.1 · 5/100 weight · pillars only
↑ listing tenure, workforce scale · ↓ market scale, operating margin
Methodology →Revenue TTM
$16.3k
Rev growth YoY (TTM)
-63.1%
Net income (FY)
-$1.4M
Employees
164
as of 2026-07-12
Market cap
$791
as of 2026-07-12
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$26.0k$26.0k2011
Net income-$1.4M-$1.4M2011
Operating income-$1.3M-$1.3M2011
Total assets$3.3M$3.3M2011
Liabilities$7.0M$7.0M2011
Equity-$3.7M-$3.7M2011
Revenue trend
FY1999 – FY2011 · USD
FY99
FY00
FY01
FY02
FY08
FY09
FY10
FY11
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Proteonomix, Inc.’s revenue?
Proteonomix, Inc. booked $26.0k in FY2011 revenue, contracting 69% year over year — slower than 86% of Healthcare companies we track, at a -5322.3% net margin.
Peers · Healthcare
Bioasis Technologies Inc.——UMC, Inc.——Talphera, Inc.46DSirona Biochem Corp.——Doseology Sciences Inc.40DSenti Biosciences, Inc.27DNeighbors
Passaic →Key facts
CEOMichael Moshe Cohen
SectorHealthcare
IndustryBiotechnology
HeadquartersHawthorne, NJ
ExchangeOTC: PROT
Employees164
IPO date1997-07-31
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.